
Despite early benefits seen in cancer patients treated with zzso zzso growth factor zzso zzso drugs, the clinical benefits obtained in terms of zzso or overall survival have been more modest than zzso This outcome is, at least in part, due to zzso drug resistance mechanisms that involve pathways zzso largely by the zzso whether intrinsic or acquired in response to therapy, or by the host, which is either responding directly to therapy or indirectly to zzso zzso The focus of this review is to zzso where possible, between such host and zzso pathways of resistance and discuss key challenges facing the zzso and clinical development of zzso agents, including potential differences in drug zzso when treating primary tumors or various stages of zzso zzso 

